pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Antibody-Drug Conjugate (ADC) · news · pharmadog
← back to Antibody-Drug Conjugate (ADC)
News · Antibody-Drug Conjugate (ADC)
230
stories
11h
nChroma halves workforce, BioXcel lets execs go
biospace
19h
AbbVie grooves with DISCO’s solid tumor tech in up to $2.5B licensing deal
biospace
2d
Lilly pens another deal, inking up to $5.9B oncology pact with Stipple
biospace
2d
Kyntra axes mid-stage ADC, adding to years of stumbles
fiercebiotech
6d
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
fiercebiotech
7d
Pfizer snags $1.5B financing from PE firm Blackstone to support Metsera asset
biospace
8d
Why a fresh approach to targeting G protein-coupled receptors could treat a rare eye cancer
fiercebiotech
8d
BioNTech pays $205M for FDA voucher to speed up ‘late-stage oncology pipeline’
fiercebiotech
8d
Capricor, NextCure shed light on recent layoffs as they gear up for approval decision, merger
fiercebiotech
12d
Could we see 10 Chinese Big Pharmas within a decade? Some CEOs think so
fiercebiotech
13d
Faeth’s phase 2 data power oral combo forward in cancer targeted by ADC heavyweights
fiercebiotech
15d
Boehringer Ingelheim strikes $7B backloaded ADC, TCE cancer deal with China's Sino
endpoints
15d
Boehringer returns to Sino Biopharma in $7.4B deal for preclinical TCEs, ADCs
fiercebiotech
15d
6 potential blockbusters that could pave China’s path to 2030 ambitions
biospace
16d
Lonza agrees to buy 5 Merck KGaA facilities to accelerate US expansion
biospace
16d
Pfizer flat in Q3 despite 32% growth for new and acquired products
biospace
17d
Significant stock movers of October: Biohaven climbs, ArriVent dives
biospace
17d
Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdict
biospace
20d
AstraZeneca employs $1.5B cost savings to reinvest back into growth
biospace
20d
AstraZeneca cuts early-phase prostate cancer pipeline
fiercebiotech
21d
Merck looks ahead to ‘another year of investment’ as Keytruda cliff looms
biospace
22d
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
biospace
22d
GSK vaccine sales miss expectations amid falling demand from adults
biospace
22d
Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025
biospace
23d
STAT+: RFK Jr. goes for broke in Iowa
stat
23d
STAT+: Nonprofit resurrects shelved gene therapy after startup shuts down
stat
23d
A possible treatment for brain-eating amoebas, found in the sea
stat
23d
STAT+: Pennsylvania Dutch country, tired of waiting for biopharma, builds drug company of its own
stat
23d
Opinion: Cancer vaccines are finally here. How do we get them to patients?
stat
23d
From RAS rivalries to leaked cancer vaccine readouts, ESMO brought the data drama
fiercebiotech
← prev
page 1 of 8
next →